

Appendix 8. Efficacy of Lipid Lowering Treatments for Secondary Cardiovascular Disease Prevention

Intervention	MACE	Cardiovascular mortality	All-cause mortality
	Median RR* (n/N)	Median RR* (n/N SR)	Median RR* (n/N SR)
<b>BAS<sup>‡</sup></b>	NR	NR	NR
<b>Ezetimibe</b>	0.94 (1/1)	NR	0.98 (0/1)
<b>Fibrates</b>	0.88 (1/1)	0.95 (0/1)	0.98 (0/1)
<b>Niacin</b>	NR	NR	NR
<b>Omega-3s (EPA+DHA)</b>	NR	NR	NR
<b>EPA only<sup>‡</sup></b>	NR	NR	NR
<b>PCSK9 Inhibitors</b>	0.84 (3/4)	0.95 (0/4)	0.94 (0/3)
<b>Statins</b>	0.80 (4/5)	0.62 (2/4)	0.99 (3/10)

Green cells represent significant results (results from at least half of the SRs were statistically significant);

\*RR < 1.0 indicates that the outcome trended in favor of the intervention; mean RR used if 2 SRs;

<sup>‡</sup>Evidence comprised of randomized controlled trials;

n/N: number of statistically significant systematic reviews/total number of systematic reviews;

MACE: major adverse cardiovascular events; RR: risk ratio; BAS: bile acid sequestrants;; EPA: eicosapentaenoic acid; NR: not reported; PCSK9: proprotein convertase subtilisin/kexin type 9